Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 29.96% |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 20.41% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -2.73% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.02% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 3.22% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 52.71% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 36.93% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 10.41% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 137.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.93% |
| Dec 31, 2025 | 38.10% |
| Sep 30, 2025 | 17.04% |
| Jun 30, 2025 | 17.37% |
| Mar 31, 2025 | -10.44% |
| Dec 31, 2024 | -12.18% |
| Sep 30, 2024 | 3.92% |
| Jun 30, 2024 | -27.59% |
| Mar 31, 2024 | 3.97% |
| Dec 31, 2023 | 10.83% |
| Sep 30, 2023 | -11.61% |
| Jun 30, 2023 | -27.19% |
| Mar 31, 2023 | -18.28% |
| Dec 31, 2022 | 32.83% |
| Sep 30, 2022 | 8.39% |
| Jun 30, 2022 | 5.02% |
| Mar 31, 2022 | 54.84% |
| Dec 31, 2021 | 34.39% |
| Sep 30, 2021 | 16.70% |
| Jun 30, 2021 | 30.28% |